Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 4
1991 4
1992 4
1997 1
2000 3
2001 6
2002 4
2003 10
2004 10
2005 12
2006 3
2007 10
2008 9
2009 9
2010 4
2011 7
2012 10
2013 9
2014 14
2015 15
2016 13
2017 13
2018 13
2019 16
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

189 results
Results by year
Filters applied: . Clear all
Page 1
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, Knapp M, Delioukina M, Kingsley E, Ping J, Beaupre DM, Neuenburg JK, Ruan J. Goy A, et al. Among authors: Dang NH. Blood. 2019 Sep 26;134(13):1024-1036. doi: 10.1182/blood.2018891598. Epub 2019 Jul 22. Blood. 2019. PMID: 31331917 Free PMC article. Clinical Trial.
Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma.
Hoffman M, Gillmor AH, Kunz DJ, Johnston MJ, Nikolic A, Narta K, Zarrei M, King J, Ellestad K, Dang NH, Cavalli FMG, Kushida MM, Coutinho FJ, Zhu Y, Luu B, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Pugh TJ, Dirks PB, Strother D, Lafay-Cousin L, Resnick AC, Scherer S, Senger DL, Simons BD, Chan JA, Morrissy AS, Gallo M. Hoffman M, et al. Among authors: Dang NH. Cancer Res. 2019 May 1;79(9):2111-2123. doi: 10.1158/0008-5472.CAN-18-3441. Epub 2019 Mar 15. Cancer Res. 2019. PMID: 30877103 Free article.
A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target.
Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. Ohnuma K, et al. Among authors: Dang NH. Front Biosci (Landmark Ed). 2018 Jun 1;23:1754-1779. Front Biosci (Landmark Ed). 2018. PMID: 29772527 Review.
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Dang NH, et al. Br J Haematol. 2018 Aug;182(4):583-586. doi: 10.1111/bjh.14820. Epub 2017 Jul 5. Br J Haematol. 2018. PMID: 28677896 Free PMC article. Clinical Trial. No abstract available.
DPP8 is a novel therapeutic target for multiple myeloma.
Sato T, Tatekoshi A, Takada K, Iyama S, Kamihara Y, Jawaid P, Rehman MU, Noguchi K, Kondo T, Kajikawa S, Arita K, Wada A, Murakami J, Arai M, Yasuda I, Dang NH, Hatano R, Iwao N, Ohnuma K, Morimoto C. Sato T, et al. Among authors: Dang NH. Sci Rep. 2019 Dec 2;9(1):18094. doi: 10.1038/s41598-019-54695-w. Sci Rep. 2019. PMID: 31792328 Free PMC article.
Biological Effects of IL-26 on T Cell-Mediated Skin Inflammation, Including Psoriasis.
Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, Dang NH, Matsuoka S, Naito H, Tominaga M, Takamori K, Morimoto C, Ohnuma K. Itoh T, et al. Among authors: Dang NH. J Invest Dermatol. 2019 Apr;139(4):878-889. doi: 10.1016/j.jid.2018.09.037. Epub 2018 Nov 10. J Invest Dermatol. 2019. PMID: 30423328 Free article.
Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis.
Hatano R, Itoh T, Otsuka H, Okamoto S, Komiya E, Iwata S, Aune TM, Dang NH, Kuwahara-Arai K, Ohnuma K, Morimoto C. Hatano R, et al. Among authors: Dang NH. MAbs. 2019 Nov-Dec;11(8):1428-1442. doi: 10.1080/19420862.2019.1654305. Epub 2019 Aug 18. MAbs. 2019. PMID: 31397631
A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth.
Goh ETH, Lin Z, Ahn BY, Lopes-Rodrigues V, Dang NH, Salim S, Berger B, Dymock B, Senger DL, Ibáñez CF. Goh ETH, et al. Among authors: Dang NH. Cell Chem Biol. 2018 Dec 20;25(12):1485-1494.e5. doi: 10.1016/j.chembiol.2018.09.007. Epub 2018 Oct 4. Cell Chem Biol. 2018. PMID: 30293939 Free article.
Degalactotigonin, a Steroidal Glycoside from Solanum nigrum, Induces Apoptosis and Cell Cycle Arrest via Inhibiting the EGFR Signaling Pathways in Pancreatic Cancer Cells.
Tuan Anh HL, Tran PT, Thao DT, Trang DT, Dang NH, Van Cuong P, Kiem PV, Minh CV, Lee JH. Tuan Anh HL, et al. Among authors: Dang NH. Biomed Res Int. 2018 Dec 16;2018:3120972. doi: 10.1155/2018/3120972. eCollection 2018. Biomed Res Int. 2018. PMID: 30643798 Free PMC article.
189 results
Jump to page
Feedback